China to blacklist wayward drug manufacturersBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g243 (Published 14 January 2014) Cite this as: BMJ 2014;348:g243
- Jane Parry
- 1Hong Kong
China’s National Health and Family Planning Commission has announced that it will blacklist drug manufacturers involved in bribery or the manufacture of substandard drugs, banning them from selling their products to public hospitals or government funded health institutions for two years.
The blacklist, due to come into effect on 1 March 2014, is part of a wider drive to clean up the country’s food and drug industries, after a spate of scandals over product safety and widespread corrupt practices between drug purchasers and providers in recent years. However, industry observers said that the measures would be effective only if …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial